%0 Journal Article
%T PCSK9及其抑制剂在急性缺血性卒中预防和治疗中的应用<br>Application of PCSK9 and Its Inhibitors in the Prevention and Treatment of Acute Ischemic Stroke
%A 韩东倩
%A 池琦
%A 董琬玥
%A 黄忆晴
%A 孟珩
%J Advances in Clinical Medicine
%P 672-679
%@ 2161-8720
%D 2025
%I Hans Publishing
%R 10.12677/acm.2025.152394
%X 在缺血性卒中的多种风险原因中&#65292;高脂血症特别是高胆固醇血症始终占有着很关键的地位&#65292;通过降低血浆中胆固醇特别是低密度脂蛋白胆固醇的水平&#65292;可以很有效地减少缺血性卒中发生的风险&#65292;这一观点已是世界神经科专家的普遍共识。他汀类药物是缺血性卒中二级预防的基石&#65292;被广泛应用于临床&#65292;然而&#65292;他汀类药物也有其自身的局限性。首先&#65292;如果他汀类药物剂量增加一倍&#65292;其降脂效果仅增加6%&#65292;这使得许多患者仅靠他汀类药物很难达到LDL-C目标。其次&#65292;有些患者不能耐受他汀类药物&#65292;这一现象在接受大剂量他汀类药物治疗的中国患者中尤为明显。近几年新上市的新型降脂药物&#8211;前蛋白转化酶枯草溶菌素9 (proprotein convertase subtilisin/kexin type 9, PCSK9)抑制剂则为缺血性卒中的治疗提供了新的策略。<br>Among the myriad risk factors for ischemic stroke, hyperlipidemia, particularly hypercholesterolemia, consistently holds a pivotal role. The reduction of plasma cholesterol levels, notably low-density lipoprotein cholesterol (LDL-C), has been recognized as an effective strategy to mitigate the risk of ischemic stroke. This perspective has garnered widespread acceptance among neurology experts globally. Statins, as the mainstay of secondary prevention for ischemic stroke, are extensively utilized in clinical settings. However, statins are not without their inherent limitations. Firstly, the lipid-lowering efficacy of statins plateaus with increased dosage; doubling the dose results in a mere 6% increase in cholesterol reduction, making it challenging for many patients to achieve their LDL-C targets with statin monotherapy. Secondly, statin intolerance is not uncommon, with a pronounced incidence observed among Chinese patients undergoing high-dose statin therapy. In this context, the advent of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel class of lipid-lowering agents, offers a promising alternative for the management of ischemic stroke, presenting a new therapeutic horizon in the field.
%K PCSK9&#65292
%K 缺血性卒中&#65292
%K 降脂<br>PCSK9
%K Ischemic Stroke
%K Lipid-Lowering
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=107481